An official website of the State of Oregon Learn How you know » (how to identify a Oregon.gov website) An official website of the State of Oregon »
You are here:
Each calendar year, the board shall identify nine drugs and at least one insulin product under ORS 646A.694 that the board determines may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state. The Oregon Prescription Drug Price Transparency program provides the board with the list of prescription drugs for review submitted under ORS 646A.689 (2) and (6), and ORS 743.025. This page contains aggregated data files for the board's affordability review as outlined in OAR 925.200.0010 and OAR 925.200.0020. The board strictly maintains the confidentiality of any information collected, used or relied upon for the review that is protected trade secret, confidential, or proprietary information, as defined in ORS 192.345.
Jan. 26, 2024 affordability review reports
Jan. 10, 2024 affordability review reports
Prescription drug and insulin list for affordability review (approved by the board on Dec. 13, 2023)
Dec. 13, 2023 board revised subset lists
On October 18, 2023, the board selected a subset list of prescription drugs pursuant to OAR 925-200-0010
Data for board review on September 20, 2023
A .gov website belongs to an official government organization in the United States.
A lock icon ( ) or https:// means you’ve safely connected to the .gov website.
Your browser is out-of-date! It has known security flaws and may not display all features of this and other websites. Learn how
×